Worth reading
69In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
64.7
%Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales3,057¥ millionYear on year +64.7%Progress 14.2%
Operating profit-222¥ million
Ordinary income-213¥ million
Net income attributable to owners of the parent249¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥14.40
Financial position at period-end
Total assets11,309¥ million
of which net assets 6,154 ¥ millionEquity ratio 53.6%vs. prior year-end -8.0pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenue
Medical Platform Business1,140,89237.3%+7.3%
Smart Clinic Business975,32331.9%+43.7%
Dental Distribution Business824,49427.0%
Other116,3323.8%
Segment profit
Medical Platform Business279,305-2.4%
Smart Clinic Business202,152+297.4%
Dental Distribution Business-69,705
Other18,163
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥21,604 million (YoY +86.8%)
Operating profit¥1,573 million (YoY +293.0%)
Ordinary income¥1,557 million (YoY +260.1%)
Profit attributable to owners of the parent¥1,190 million (YoY +332.5%)
Annual Dividend ForecastPrevious-period results ¥30 / Current fiscal year forecast ¥30 / Change ¥0 / Change rate ¥0
Factors Behind Changes in Business Performance
Increases in Medical DOC page views, 1,289 contracts for medical institution introduction articles and other services, improvements to AI-related services and stronger proposals for their introduction, and an increase in newly adopting clinics, among other factors. Extraordinary income, including ¥497.319 million in income from the reversal of stock acquisition rights, contributed to net income.
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 1 / Company name 有限会社アカサカ歯材社 / Excluded Number of companies 0 / Company name Not disclosed
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥469 thousand, Gain on reversal of subscription rights to shares ¥497,319 thousand / Extraordinary loss Not disclosed
Depreciation and amortization¥15,782 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional and individual investors)
Issued Shares at Period-End17,838,100 Shares
Treasury Shares at Period-End500,068 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥3,057 million (YoY +64.7%) |
| Operating profit | ¥-222 million |
| Ordinary income | ¥-213 million |
| Profit attributable to owners of the parent | ¥249 million |
| Net income per share | ¥14.40 |
| Equity ratio | End of the current fiscal period 53.6 / End of previous period 61.6 |
| Total assets | ¥11,309 million |
| Net assets | ¥6,154 million |
| Full-year earnings forecast | Net Sales ¥21,604 million (YoY +86.8%) / Operating profit ¥1,573 million (YoY +293.0%) / Ordinary income ¥1,557 million (YoY +260.1%) / Profit attributable to owners of the parent ¥1,190 million (YoY +332.5%) |
| Annual Dividend Forecast | Previous-period results ¥30 / Current fiscal year forecast ¥30 / Change ¥0 / Change rate ¥0 |
| Segment revenue | Medical Platform Business ¥1,140,892 thousand (YoY +7.3%) / Smart Clinic Business ¥975,323 thousand (YoY +43.7%) / Dental Distribution Business ¥824,494 thousand / Other ¥116,332 thousand |
| Segment profit | Medical Platform Business ¥279,305 thousand (YoY -2.4%) / Smart Clinic Business ¥202,152 thousand (YoY +297.4%) / Dental Distribution Business ¥-69,705 thousand / Other ¥18,163 thousand |
| Depreciation and amortization | ¥15,782 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥469 thousand, Gain on reversal of subscription rights to shares ¥497,319 thousand / Extraordinary loss Not disclosed |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 1 / Company name 有限会社アカサカ歯材社 / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional and individual investors) |
| Issued Shares at Period-End | 17,838,100 Shares |
| Treasury Shares at Period-End | 500,068 Shares |
| Factors Behind Changes in Business Performance | Increases in Medical DOC page views, 1,289 contracts for medical institution introduction articles and other services, improvements to AI-related services and stronger proposals for their introduction, and an increase in newly adopting clinics, among other factors. Extraordinary income, including ¥497.319 million in income from the reversal of stock acquisition rights, contributed to net income. |
Items this document does not state (12)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Each business grew due to an increase in Medical DOC page views, growth in the number of contracts, improvements to and stronger proposals for the introduction of AI-related services, and other factors. Net income included extraordinary income, including ¥497.319 million in income from the reversal of stock acquisition rights.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.